← Browse by Condition
Medical Condition

her2 negative

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for her2 negative sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — her2 negative Clinical Trials

How many clinical trials are currently recruiting for her2 negative?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for her2 negative, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for her2 negative?
her2 negative research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a her2 negative clinical trial?
Eligibility criteria for her2 negative trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Qilu Hospital of Shandong University 1 trial
Jiangsu Hansoh Pharmaceutical Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT06932068 Phase 2
Recruiting
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
Enrollment
77 pts
Location
China
Sponsor
Qilu Hospital of Shandong Univ...
View Trial →
NCT06769425 Phase 1
Recruiting
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Enrollment
157 pts
Location
China
Sponsor
Jiangsu Hansoh Pharmaceutical ...
View Trial →

Related Conditions

low pd l1 expressing (1) unresectable or metastatic gastric gastroesophageal junction adenocarcinoma (1) recurrent ovarian cancer (1) advanced breast cancer (1) tnbc (1) advanced prostate cancer (1) advanced gastric cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology